Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15254587 | 0.92 | MKNK1 (0.44) | HCAR3MKNK1NTRK1NTRK3NTRK2 | |
| SCHEMBL20119801 | 0.88 | NTRK1 (0.39) | MKNK1NTRK1NTRK3NTRK2BRD4 | |
| SCHEMBL15258024 | 0.85 | MKNK1 (0.43) | MKNK1NTRK1NTRK3NTRK2BRD4 | |
| SCHEMBL16371971 | 0.79 | NTRK1 (0.60) | MKNK1NTRK1NTRK3NTRK2BRD4 | |
| SCHEMBL16023624 | 0.75 | MKNK1 (0.39) | HCAR3MKNK1NTRK1NTRK3NTRK2 | |
| SCHEMBL16468193 | 0.75 | NTRK1 (0.47) | MKNK1NTRK1NTRK3NTRK2KDM4E | |
| SCHEMBL23932105 | 0.75 | CRHR1 (0.35) | MKNK1 | |
| SCHEMBL15254634 | 0.74 | MKNK1 (0.41) | MKNK1NTRK1NTRK3NTRK2MAPT | |
| SCHEMBL16468273 | 0.73 | NTRK1 (0.46) | MKNK1NTRK1NTRK3NTRK2KDM4E | |
| SCHEMBL16468487 | 0.73 | NTRK1 (0.46) | MKNK1NTRK1NTRK3NTRK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | HNRNPR, HNRNPAB, RBM3 | HCAR3 1783/4885MKNK1 1675/4885NTRK1 721/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | HCAR3 1783/4885MKNK1 1675/4885NTRK1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.